137 related articles for article (PubMed ID: 32725376)
21. Risk factors of sudden unexpected death in patients with advanced cancer near the end of life.
Taniyama T; Tokutani R; Hiramoto S
Palliat Support Care; 2022 Dec; 20(6):818-822. PubMed ID: 34607625
[TBL] [Abstract][Full Text] [Related]
22. A retrospective observational study to estimate the attrition of patients across lines of systemic treatment for metastatic colorectal cancer in Canada.
Kennecke H; Berry S; Maroun J; Kavan P; Aucoin N; Couture F; Poulin-Costello M; Gillesby B
Curr Oncol; 2019 Dec; 26(6):e748-e754. PubMed ID: 31896945
[TBL] [Abstract][Full Text] [Related]
23. Impact of palliative chemotherapy and best supportive care on overall survival and length of hospitalization in patients with incurable Cancer: a 4-year single institution experience in Japan.
Murakawa Y; Sakayori M; Otsuka K
BMC Palliat Care; 2019 Jun; 18(1):45. PubMed ID: 31159782
[TBL] [Abstract][Full Text] [Related]
24. Safety and antitumor activity of arsenic trioxide plus infusional 5-fluorouracil, leucovorin, and irinotecan as second-line chemotherapy for refractory metastatic colorectal cancer: A pilot study from South India.
Lakshmaiah KC; Chaudhuri T; Babu GK; Lokanatha D; Jacob LA; Suresh Babu MC; Rudresha AH; Lokesh KN; Rajeev LK
Indian J Cancer; 2017; 54(4):631-633. PubMed ID: 30082548
[TBL] [Abstract][Full Text] [Related]
25. Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US.
Kerekes DM; Frey AE; Prsic EH; Tran TT; Clune JE; Sznol M; Kluger HM; Forman HP; Becher RD; Olino KL; Khan SA
JAMA Oncol; 2024 Mar; 10(3):342-351. PubMed ID: 38175659
[TBL] [Abstract][Full Text] [Related]
26. How are elderly patients treated after a diagnosis of metastatic colorectal cancer in real-life practice? A study in a French teaching hospital.
Gouverneur A; Rouyer M; Grelaud A; Robinson P; Colombani F; Terrebonne E; Smith D; Fourrier-Réglat A; Noize P
Fundam Clin Pharmacol; 2017 Feb; 31(1):104-109. PubMed ID: 27600062
[TBL] [Abstract][Full Text] [Related]
27. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Heinemann V; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Hielscher J; Scholz M; Müller S; Link H; Niederle N; Rost A; Höffkes HG; Moehler M; Lindig RU; Modest DP; Rossius L; Kirchner T; Jung A; Stintzing S
Lancet Oncol; 2014 Sep; 15(10):1065-75. PubMed ID: 25088940
[TBL] [Abstract][Full Text] [Related]
28. Modern-day palliative chemotherapy for metastatic colorectal cancer: does colonic resection affect survival?
Lau JWL; Chang HSY; Lee KY; Gwee YX; Lee WQ; Chong CS
ANZ J Surg; 2018 Nov; 88(11):E772-E777. PubMed ID: 29938886
[TBL] [Abstract][Full Text] [Related]
29. Palliative Chemotherapy Affects Aggressiveness of End-of-Life Care.
Wu CC; Hsu TW; Chang CM; Lee CH; Huang CY; Lee CC
Oncologist; 2016 Jun; 21(6):771-7. PubMed ID: 27091417
[TBL] [Abstract][Full Text] [Related]
30. Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients.
Song A; Eo W; Lee S
World J Gastroenterol; 2015 Nov; 21(43):12410-20. PubMed ID: 26604648
[TBL] [Abstract][Full Text] [Related]
31. Clinico-pathological correlation of serial measurement of circulating tumor cells in 24 metastatic colorectal cancer patients receiving chemotherapy reveals interpatient heterogeneity correlated with CEA levels but independent of KRAS and BRAF mutation.
Das A; Kunkel M; Joudeh J; Dicker DT; Scicchitano A; Allen JE; Sarwani N; Yang Z; Kaifi J; Zhu J; Liao J; El-Deiry WS
Cancer Biol Ther; 2015; 16(5):709-13. PubMed ID: 25806877
[TBL] [Abstract][Full Text] [Related]
32. Effects of Social and Contextual Factors Including Marital Status and Children on the Use of Palliative Chemotherapy in Metastatic Colorectal Cancer.
Ahmed S; Baig T; Iqbal N; Le D; Chalchal H; Zaidi A; Pahwa P
Am J Clin Oncol; 2019 Apr; 42(4):363-366. PubMed ID: 30789411
[TBL] [Abstract][Full Text] [Related]
33. Influence of comorbidity, age and performance status on treatment efficacy and safety of cetuximab plus irinotecan in irinotecan-refractory elderly patients with metastatic colorectal cancer.
Jehn CF; Böning L; Kröning H; Pezzutto A; Lüftner D
Eur J Cancer; 2014 May; 50(7):1269-75. PubMed ID: 24503027
[TBL] [Abstract][Full Text] [Related]
34. Chemotherapy use and adoption of new agents is affected by age and comorbidities in patients with metastatic colorectal cancer.
Vijayvergia N; Li T; Wong YN; Hall MJ; Cohen SJ; Dotan E
Cancer; 2016 Oct; 122(20):3191-3198. PubMed ID: 27379436
[TBL] [Abstract][Full Text] [Related]
35. Palliative chemotherapy for gastroesophageal cancer in old and very old patients: A retrospective cohort study at the National Center for Tumor Diseases, Heidelberg.
Berger AK; Zschaebitz S; Komander C; Jäger D; Haag GM
World J Gastroenterol; 2015 Apr; 21(16):4911-8. PubMed ID: 25945004
[TBL] [Abstract][Full Text] [Related]
36. Utilisation of systemic therapy options in routine treatment of metastatic colorectal cancer in Australia.
Delahunty R; Lee M; Wong HL; Johns J; Mckendrick J; Lee B; Kosmider S; Cooray P; Ananda S; Desai J; Tran B; Tie J; Gibbs P; Wong R
Intern Med J; 2020 Feb; 50(2):165-172. PubMed ID: 30887616
[TBL] [Abstract][Full Text] [Related]
37. Rising and Falling Trends in the Use of Chemotherapy and Targeted Therapy Near the End of Life in Older Patients With Cancer.
Fang P; Jagsi R; He W; Lei X; Campbell EG; Giordano SH; Smith GL
J Clin Oncol; 2019 Jul; 37(20):1721-1731. PubMed ID: 31141431
[TBL] [Abstract][Full Text] [Related]
38. Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial.
Romera A; Peredpaya S; Shparyk Y; Bondarenko I; Mendonça Bariani G; Abdalla KC; Roca E; Franke F; Melo Cruz F; Ramesh A; Ostwal V; Shah P; Rahuman SA; Paravisini A; Huerga C; Del Campo García A; Millán S
Lancet Gastroenterol Hepatol; 2018 Dec; 3(12):845-855. PubMed ID: 30262136
[TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of aflibercept in combination with fluorouracil, leucovorin and irinotecan in the treatment of Asian patients with metastatic colorectal cancer.
Chong DQ; Manalo M; Imperial M; Teo P; Yong G; Ng M; Tan IB; Choo SP; Chua C
Asia Pac J Clin Oncol; 2016 Sep; 12(3):275-83. PubMed ID: 27075236
[TBL] [Abstract][Full Text] [Related]
40. Chemotherapy Near the End of Life for Chinese Patients with Solid Malignancies.
Sheng J; Zhang YX; He XB; Fang WF; Yang YP; Lin GN; Wu X; Li N; Zhang J; Zhai LZ; Zhao YY; Huang Y; Zhou NN; Zhao HY; Zhang L
Oncologist; 2017 Jan; 22(1):53-60. PubMed ID: 27789776
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
